CISSPECT DESK-LAB
The world's first fully automated synthesis module
22 July 2020
The automated DESK-LAB process:
Ensures a high quality reproduction of each radiopharmaceutical batch
Reduces and simplifies the handling of radioactive material by the radiochemistry lab scientists
Automated GMP synthesis at your desk!
CISSPECT DESK-LAB represents a great leap forward for the development of radiopharmaceuticals and personalised drug discovery. Recently, we have developed the world’s first fully automated synthesis module, CISSPECT DESK-LAB, for the synthesis of Pt-195m cisplatin and other platinum compounds
The module has been designed for the production of GMP Pt-195m Cisplatin to facilitate a human pilot study. We have achieved this in close collaboration with our industrial partner FutureChemistry and renowned Dutch Academic Medical Centres.
process steps leading to results
DISSOLVE
REDUCE
IODINATE
AMINATE
HYDROLYSE
CHLORINATE
DISPENSE
Partner: FutureChemistry
CISSPECT DESK-LAB represents a great leap forward for the development of radiopharmaceuticals and personalised drug discovery. Recently, we have developed the world’s first fully automated synthesis module, CISSPECT DESK-LAB, for the synthesis of Pt-195m cisplatin and other platinum compounds
The module has been designed for the production of GMP Pt-195m Cisplatin to facilitate a human pilot study. We have achieved this in close collaboration with our industrial partner FutureChemistry and renowned Dutch Academic Medical Centres.
“A great leap forward for the development of radiopharmaceuticals and personalised drug discovery.“
CISSPECT = Pt-195m = radioactive cisplatin
CISSPECT DESK-LAB represents a great leap forward for the development of radiopharmaceuticals and personalised drug discovery. Recently, we have developed the world’s first fully automated synthesis module, CISSPECT DESK-LAB, for the synthesis of Pt-195m cisplatin and other platinum compounds
The module has been designed for the production of GMP Pt-195m Cisplatin to facilitate a human pilot study. We have achieved this in close collaboration with our industrial partner FutureChemistry and renowned Dutch Academic Medical Centres.
CISSPECT® DESK-LAB - Automated GMP synthesis at your desk!
Human Pilot
The feasibility of SPECT imaging and quantification of Pt-195m in a preclinical setting has already been shown (E.A. Aalbersberg et al., EJNMMI 2017 (44), 8, 1347 – 1354). As a next step, the feasibility in humans will be assessed. If successful, Pt-195m cisplatin contributes to optimising treatment outcome of chemo(radio)therapy and reducing toxicity in a personalised approach.
